Translation of the instructions can be
GEMOPROCT rectal suppositories
Instruction
For medical use of the medicinal product
Hemoproct
(Hemoproct)
Composition:
Active ingredients: benzocaine, bismuth subgallate, zinc oxide, menthol;
1 suppository contains benzocaine 100 mg, bismuth subgallate 40 mg, zinc oxide 20 mg, menthol 4 mg;
excipients: polyethylene oxide 1500, polyethylene oxide 400.
Dosage form.
Rectal suppositories.
Main physicochemical properties: Smooth suppositories of greenish-yellow color, uniform consistency. The presence of a funnel-shaped depression and an air core is allowed.
Pharmacotherapeutic group.
Antihemorrhoidal agents for topical use. Preparations containing local anesthetics. ATC code c05a d03.
Pharmacological properties.
Pharmacodynamics.
Hemoproct is a complex drug, the therapeutic effect of which is due to the pharmacological properties of the active components included in its composition. Hemoproct has a local anesthetic, anti-inflammatory and astringent effect.
Pharmacokinetics.
Didn't study.
Clinical characteristics.
Indication.
Symptomatic therapy of hemorrhoids and anal fissures.
Contraindication.
Hypersensitivity to the components of the drug.
Interaction with other drugs and other types of interactions.
It is not recommended to use the drug without strict medical indications and medical supervision while regularly taking monoamine oxidase inhibitors (MAOIs), antidepressants, and antihypertensives due to the theoretical possibility of reducing the effect of MAOIs or enhancing the effect of antihypertensives due to interaction with benzocaine in cases where the recommended doses and duration of administration are significantly exceeded.
Application features.
With prolonged use of the drug, monitoring of blood parameters is necessary.
In case of heavy bloody discharge from the anus or if symptoms of the disease are present within 7 days of treatment, additional consultation with a proctologist is necessary.
You should consult a doctor before using this drug in the following cases: severe arterial hypertension, severe heart rhythm disturbances, clinically pronounced thyrotoxicosis, urination disorders.
The smallest amount of the drug necessary should be used. There are reports that the use of drugs containing benzocaine can cause methemoglobinemia. Symptoms such as cyanosis of the skin, lips and nail beds, headache, dizziness, shortness of breath (difficulty breathing), weakness, tachycardia, which may occur during treatment, may indicate methemoglobinemia, which is potentially life-threatening and requires urgent medical intervention.
Use during pregnancy or breastfeeding.
Women during pregnancy or breastfeeding are prescribed the drug, taking into account the benefit/risk ratio.
The ability to influence the reaction speed when driving vehicles or other mechanisms.
When treating with the drug, it is recommended to refrain from driving vehicles and performing work that requires increased attention and precise coordination.
Method of administration and doses.
Before use, the suppository should be removed from the blister. The drug is used rectally. 1 suppository is administered 1-2 times a day after a cleansing enema or spontaneous defecation. The duration of the treatment course is determined by the course and severity of the disease, the achieved therapeutic effect, and the general treatment tactics.
Children.
There are no data on the use of the drug in children.
Overdose.
When used in therapeutic doses, overdose is unlikely.
Symptoms of overdose may be associated with the pharmacological effects of benzocaine. Its systemic absorption in overdose may manifest as drowsiness, anxiety, agitation, and in severe cases, convulsions. There are reports that the appointment of drugs containing benzocaine can cause methemoglobinemia. Symptoms such as cyanosis of the skin, lips and nail beds, headache, dizziness, shortness of breath (difficulty breathing), weakness, tachycardia, which may occur during treatment, may indicate methemoglobinemia, which is potentially life-threatening and requires urgent medical intervention.
Emergency care for overdose and development of methemoglobinemia consists of intravenous administration of methylene blue. Other symptoms of overdose require discontinuation of the drug and symptomatic treatment.
Adverse reactions.
Sometimes there are contact dermatitis, allergic reactions, including hyperemia, skin rashes, itching. The drug can cause a laxative effect, the appearance of a burning sensation in the anus. With prolonged use, reactions from the blood - methemoglobinemia (cyanosis of the skin, lips and nail beds, headache, dizziness, shortness of breath, weakness, tachycardia) may develop.
Expiration date.
2 years.
Storage conditions.
Store in original packaging at a temperature not exceeding 25 ° C. Keep out of the reach of children.
Packaging.
5 suppositories in a strip, 2 strips in a pack.
Vacation category.
Without a prescription.
Producer.
LLC "Pharmex group".
Ukraine, 08301, Kyiv region, Boryspil city, Shevchenko st., building 100.
